Drug Study

Generic Name Classifcation Indication Dosage Nursing Responsibilities

Acetaminophe
n
Non-Opioid Analgesic/
Antipyretic
Mild to moderate
pain.
Fever control.
100 mg/mL, 160 mg/5 mL
O!"# ON$#" %#A& '!A"(ON
%O 0.5)1 *r 1)+ *r +), *r-
(. //in +0 min +0 min 0)6 *r
1al2-li2e3 Neonates3 4)5 *r. Ad5lts3 1)+ *r.
PO (Adults and Children >12 yr): +45)650
mg 6 0)6 *r or 1 g +)0 times daily or 1+00
mg 6 , *r 7not to e8ceed 0 g or 4.5 g/40 *r in
patients /it* *epatic/renal impairment9.
PO (Children 112 yr): 10)15 mg/:g/dose 6
0)6 *r as needed 7not to e8ceed 5 doses/40
*r9.
PO (Infants): 10)15 mg/:g/dose 6 0)6 *r as
needed 7not to e8ceed 5 doses/40 *r9.
Monitor liver and :idney 25nction, and
;<; periodically 2or clients on long-term
t*erapy.
;an ca5se psyc*ologic dependence.
Antidote3 Acetylcysteine 7M5comyst9

Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
Tylenol Analgesia3 in*i=its
2ormation o2
prostaglandins involved
/it* pain. Analgesia also
occ5rs =y action o2
*ypot*alam5s and =loc:ing
generation o2 pain
imp5lses.
Antipyretic3 in*i=its
2ormation o2
prostaglandins in
prod5ction o2 2ever. (t acts
on t*e *ypot*alam5s to
prod5ce vasodilation.
'oes not *ave anti-
in>ammatory or
antiplatelet action.

1ypersensitivit
y
$evere *epatic
impairment/
active liver
disease.

as*
"*rom=ocytopenia
Liver "o8icity 7to8icity can occ5r 4)40
*o5rs a2ter ingestion9
N/A
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Morphine 1istamine 14
Antagonist
$*ort-term treatment o2 active
d5odenal 5lcers and =enign gastric
5lcers.
Maintenance t*erapy 2or d5odenal
and gastric 5lcers a2ter *ealing o2
active 5lcers.
Management o2 @#'.
45 mg/ml Assess 2or epigastric or a=dominal pain and 2ran: or
occ5lt =lood in t*e stool, emesis, or gastric aspirate.
Trade Name Mechanism of
Action
Contraindication Aderse !"ects Actual #atient Response
2lcin (n*i=its t*e
action o2
*istamine at t*e
14-receptor site
located primarily
in gastric
parietal cells,
res5lting
in in*i=ition o2
gastric acid
secretion.
1ypersensitivity ;N$3 con25sion, diAAiness,
dro/siness,
*all5cinations,
*eadac*e.
;.3 A1B"1M(A$.
@(3 constipation, diarr*ea,
na5sea. #ndo3 gynecomastia.
1emat3A@AN!LO;B"O$($,
anemia,
ne5tropenia,
t*rom=ocytopenia. Local3
pain at (M site.
Misc3 *ypersensivity
reactions,
vasc5litis.
N/A
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor p5lse,
<%, respirations, and #;@ 2re65ently t*ro5g*o5t
administration o2 parenteral magnesi5m s5l2ate.
espirations s*o5ld =e at least 16/min =e2ore eac*
dose.
Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy.
(nstit5te seiA5re preca5tions.
%atellar re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore
eac* parenteral dose o2 magnesi5m s5l2ate. (2
response is a=sent, no additional doses s*o5ld =e
administered 5ntil positive response is o=tained.
Monitor ne/=orn 2or *ypotension, *ypore>e8ia, and
respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100 mL/0
*r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar e8cita=ility.
1ypermagnesemia
1ypocalcemia
An5ria
1eart =loc:
;N$3 dro/siness.
esp3prespiratory rate.
;.3 arr*yt*mias, =radycardia,
*ypotension.
@(3 diarr*ea.
M$3 m5scle /ea:ness.
'erm3 >5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Drug Study
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A
Chong $ua $ospital
'on Mariano ;5i $t. corner ?. Llorente $t., ;e=5 ;ity, %*ilippines 6000
%&ce of the Critical Care Serices Tel' (
)**'+,,, loc' -./*
!ducation0 Training 1 Research
Drug Study
Generic
Name
Classifcation Indication Dosage Nursing Responsibilities
Magnesium
Sulfate
Mineral and #lectrolyte
eplacement
"reatment/prevention o2
*ypomagnesemia.
"reatment
o2 *ypertension.
Anticonv5lsant associated
/it* severe eclampsia, pre-
eclampsia, or ac5te
nep*ritis.
500mg/ml 1ypomagnesemia/Anticonv5lsant3 Monitor
p5lse, <%, respirations, and #;@ 2re65ently
t*ro5g*o5t administration o2 parenteral magnesi5m
s5l2ate. espirations s*o5ld =e at least 16/
min =e2ore eac* dose.
D Monitor ne5rologic stat5s =e2ore and t*ro5g*o5t
t*erapy. (nstit5te seiA5re preca5tions. %atellar
re>e8 7:nee Cer:9 s*o5ld =e tested =e2ore eac*
parenteral dose o2 magnesi5m s5l2ate. (2 response
is a=sent, no additional doses s*o5ld =e
administered
5ntil positive response is o=tained.
D Monitor ne/=orn 2or *ypotension, *ypore>e8ia,
and respiratory depression i2 mot*er *as received
magnesi5m s5l2ate.
D Monitor inta:e and o5tp5t ratios. !rine o5tp5t
s*o5ld =e maintained at a level o2 at least 100
mL/0 *r.
Trade Name Mechanism of Action Contraindication Aderse !"ects Actual #atient Response
#ssential 2or t*e
activity o2 many
enAymes. %lays an
important role in
ne5rotransmission and
m5sc5lar
e8cita=ility.
1ypermagnesemiaE
1ypocalcemiaE
An5riaE 1eart =loc:E
O<3 !nless 5sed 2or
preterm
la=or, avoid
contin5o5s 5se d5ring
active la=or
or /it*in 4 *r o2
delivery d5e to
potential 2or
magnesi5m
to8icity in ne/=orn.
;N$3 dro/siness.
esp3prespiratory rate. ;.3
arr*yt*mias,
=radycardia, *ypotension. @(3
diarr*ea.
M$3 m5scle /ea:ness. 'erm3
>5s*ing, s/eating.
Meta=3 *ypot*ermia.
N/A